Daylong introduces UK’s first dedicated wound management solution for Hidradenitis Suppurativa (HS)

Leading wound care specialist and NHS supplier Daylong is introducing an innovative wound management solution, HidraWear, to the UK. Award-winning HidraWear is the world’s first adhesive-free wound care solution specifically designed for people with Hidradenitis Suppurativa (HS).

Hidradenitis Suppurativa is a chronic, inflammatory skin disease that causes recurrent and painful nodules, boils, abscesses and lesions of the skin. This recurrent, and often painful, disease is frequently overlooked and can have a profound impact on patients’ quality of life. The lesions usually occur near hair follicles where there are sweat glands, around the groin, bottom, breasts and armpits – some of the toughest places to dress and retain a dressing. HidraWear offers an effective alternative to the wound dressings currently available for patients and healthcare practitioners treating patients with HS.

The HidraWear range includes a body conforming garment , a super absorbent wound dressing and an external fastening tab which improves the quality of life for HS patients in the following ways:

  • Adhesive free – adhesive dressings can cause irritation and additional pain
  • No tape or bandages – HidraWear is easier and quicker to apply
  • Snug and secure – unlike less suitable dressings, HidraWear gives ample coverage and will not fall off causing patients embarrassment
  • Body conforming – HS wounds tend to be in convex areas of the body. HidraWear conforms to these areas for a better fit.

Mark Hudston, Sales & Marketing Director at Daylong commented: “We are delighted to be able to bring such an innovative solution to the UK and improve the quality of life of patients living with HS. We believe that HS is going undiagnosed in many patients in the UK, as the prevalence here is reported as much less than in Ireland where there is greater awareness of the disease. We are committed to offering the very best service to our customers, supplying the widest range of compression and wound care products, speedy delivery and expert advice. What’s more, we aim to have HidraWear available on Drug Tariff by the end of 2021.”

Suzanne Moloney, CEO and founder of HidraWear, who has been living with HS for decades, added: “We’ve set a precedent by successfully listing HidraWear for reimbursement through the public health service in Ireland, making it the first country in the world to make HS specific dressings available through its public health provision. We look forward to working with Daylong on making the UK the second country to take this important step.”